

## ASX Announcement

### Company Announcements Platform

#### Placement Cleansing Notice under ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (Instrument)

MELBOURNE, 28 October 2020, Anatara Lifesciences Limited (ASX: ANR) ('Anatara' or 'Company') announced on 21 October 2020 its intention to conduct a share purchase plan (**SPP**) to raise up to \$750,000 (before costs), pursuant to which eligible shareholders will have the opportunity to apply for up to \$30,000 worth of fully-paid ordinary shares in the Company (**New Shares**).

The New Shares will be issued at a price of 80% of the VWAP of the ordinary shares in Anatara calculated over the last 5 days on which sales in ordinary shares were recorded before the day on which the issue of SPP Shares will be made, subject to a floor price of \$0.15 per SPP Share in the event the 80% VWAP is less than \$0.15 (**SPP Offer**).

The SPP Offer opens on 28 October 2020 and the SPP Offer Booklet (**SPP Booklet**) will be sent to eligible shareholders and lodged with the ASX on the same date.

In respect of the SPP Offer, the Company gives notice as required under *Corporations Act 2001* (Cth) (**Act**) and ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (**Instrument**) that:

- 1 the Company will be issuing the New Shares under the SPP without disclosure to eligible shareholders under Part 6D.2 of the Act;
- 2 this notice is being given to the ASX by the Company under section 708A(5)(e) of the Act and in accordance with the Instrument;
- 3 as at the date of this notice, the Company has complied with:
  - (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
  - (b) section 674 of the Act; and
- 4 as at the date of this notice, there is no "excluded information" as defined in section 708A(7) or 708A(8) of the Act that has not already been disclosed to investors generally.

This announcement was approved by the full Board of the Company.



**For more information please contact:**

<b>General inquiries</b>	
Steven Lydeamore CEO, Anantara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anantara.com	Sue MacLeman Chair, Anantara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anantara.com

**About Anantara Lifesciences Ltd**

Anantara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anantara is a life sciences company with expertise in developing products for animal and human health. Anantara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Yours faithfully



Stephen Denaro  
Company Secretary  
**Anantara Lifesciences Limited**